Scientific Meeting: Psychedelics: Clinical Applications in Psychoanalytic Practice

  •  December 9, 2025
     8:00 pm - 10:00 pm

***This meeting is virtual and will be held on ZOOM.***

NYPSI’s 1081st Scientific Meeting:

“Psychedelics: Clinical Applications in Psychoanalytic Practice”

Tuesday, December 9, 2025

8:00 – 10:00 PM (EST)

Presenters: Jeffrey Guss, M.D., Charis Cladouhos, M.D., & Shuli Sandler, Psy.D.

This panel is designed for clinicians who want to learn more about psychedelics with the possibility of gaining further training in the use of psychedelics clinically for their patients.

Presenters are experts in the field of the clinical use of psychedelics. Through a discussion of clinical material, they will consider the use of psychedelics in relation to psychoanalytic treatment.

2 Contact Hours. 2 CME/CE credits will be offered. See details below.

General Admission: $50

Student Admission: $35

Free Admission for current NYPSI members/students and HFI Candidates

REGISTRATION LINK HERE

Please note registration closes at 5 PM on Monday, December 8th.

THIS MEETING IS VIRTUAL; READ INSTRUCTIONS BELOW:

***Registration in Zoom Before the Meeting is Required to Attend***

After you have completed registering for the event, please look out for a confirmation email with more details on how to receive your Zoom Link.

Evaluation Survey and CME/CE documentation will be emailed after the event.

Please make sure you type your email correctly when you register!  Contact with questions.

OPTIONAL READINGS
    1. Bender, D., & Hellerstein, D. J. (2022). Assessing the risk-benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research. Psychopharmacology, 239(6), 1907–1932. https://doi.org/10.1007/s00213-021-06049-6
    2. Evans, J., Robinson, O. C., Argyri, E. K., Suseelan, S., Murphy-Beiner, A., McAlpine, R., Luke, D., Michelle, K., & Prideaux, E. (2023). Extended difficulties following the use of psychedelic drugs: A mixed methods study. PloS one, 18(10), e0293349. https://doi.org/10.1371/journal.pone.0293349
    3. Guss, J. (2022). A Psychoanalytic Perspective on Psychedelic Experience, Psychoanalytic Dialogues, 32:5, 452-468, doi: 10.1080/10481885.2022.2106140 
    4. Hartogsohn I. (2017). Constructing drug effects: A history of set and setting. Drug Science, Policy and Law. 2017;3. doi:10.1177/2050324516683325
BIOGRAPHIES
Charis Cladouhos, M.D. is a child, adolescent, and adult psychiatrist and psychoanalyst with an interest in the treatment of trauma. She is also trained in EMDR, DBR, ketamine and MDMA-assisted psychotherapy. A faculty member at the Boston Psychoanalytic Society and Institute and Tufts University School of Medicine, as well as the incoming Chair of the Psychoanalytic Special Interest Group for the International Society for the Study of Trauma and Dissociation, Dr. Cladouhos has taught courses at BPSI on Developmental Trauma and Psychedelic-Assisted Psychotherapy. She has been interviewed by the On the Couch IPA podcast on the topic of psychoanalysis and psychedelic-assisted therapy. She has been course director of the Healer’s Art Elective at Tufts University School of Medicine and organized the first hospital-sponsored retreat for physicians at Tufts Medical Center during the pandemic. Dr. Cladouhos has a private practice in Waban, Massachusetts.
*
Shuli Sandler, Psy.D. is a clinical psychologist licensed to practice in New York and New Jersey. Her areas of specialty include working with the full-age range of development from children through elder adulthood. She has experience diagnosing and treating anxiety disorders, depression, ADHD, Asperger’s, and academic difficulties. Dr. Sandler is a psychoanalyst and received her certification to practice psychoanalysis from New York Psychoanalytic Society & Institute. Dr. Sandler also provides psychedelic integration and ketamine-assisted psychotherapy.
*

Jeffrey Guss, MD is a psychiatrist, psychoanalyst, researcher and teacher with an interest in the integration of psychoanalytic therapy and psychedelic therapy. He is Clinical Assistant Professor of Psychiatry at the New York University Langone School of Medicine and was Co-Principal Investigator and Director of Psychedelic Psychotherapy for the NYU Psilocybin Cancer Anxiety Research Project. He has been a study therapist with numerous clinical trials of psychedelic therapy, including Psilocybin-Assisted treatment of Major Depressive Disorder and MDMA-assisted Psychotherapy for Post-Traumatic Stress Disorder. Dr. Gus is on the faculty of the NYU Postdoctoral Program in Psychotherapy and Psychoanalysis and has published on the topics of gender and sexuality in Psychoanalysis Culture and Society. He is Lead Trainer and Psychoanalytic Program Director at Fluence Continuing Education for Psychedelic Psychotherapy and he lectures on Acceptance and Commitment Therapy, Psychoanalytic Explorations of Psychedelic Experience, and provides Continuing Case Conferences on Ketamine Assisted Psychotherapy. He has over 22 publications related to the use of Psychedelic Medicines and lectures internationally on Psychoanalysis and Psychedelic Assisted Psychotherapy. Dr. Gus has recently published “A Psychoanalytic Perspective on Psychedelic Experience” in the most recent issue of Psychoanalytic Dialogues. He maintains a private practice of psychotherapy, psychoanalysis, and Ketamine Assisted Psychotherapy in New York City.

CONTINUING EDUCATION

Educational Objectives: Upon completion of this activity, participants should be able to:

  1. Explain the therapeutic use of psychedelics to treat various psychiatric disorders.
  2. Summarize how the use of psychedelics can enhance the work of psychoanalysis clinically.

Psychologists

New York Psychoanalytic Society & Institute is recognized by the New York State Education Department’s State Board for Psychology as an approved provider of continuing education for licensed psychologists #PSY – 0073.

New York Psychoanalytic Society & Institute is approved by the American Psychological Association (APA) to sponsor continuing education programs for psychologists. New York Psychoanalytic Society & Institute maintains responsibility for this program and its content. DISCLOSURE: None of the planners and presenters of this CE program has any relevant financial relationships to disclose.

Social Workers

New York Psychoanalytic Society & Institute is recognized by the New York State Education Department’s State Board for Social Work as an approved provider of continuing education for licensed social workers #SW – 0317.

Physicians
ACCME Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of American Psychoanalytic Association and New York Psychoanalytic Society & Institute. The American Psychoanalytic Association is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement
The American Psychoanalytic Association designates this live activity for a maximum of [2] AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure Statement

None of the planners and presenters for this educational activity have relevant financial relationship(s)* to disclose with ineligible companies* whose primary business is producing, marketing, selling, re-selling or distributing healthcare products used by or on patients. *Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

/by